Founded

CBP501 Phase 2 global study for MPM (CBP501 + Cisplatin ± Pemetrexed) initiated

CBP501 Phase 2 global study for NSCLC (CBP501 + CDDP ± Pemetrexed) initiated

CBP501 Orphan drug designation from FDA for MPM

CBS9106 licensed out to Stemline Therapeutics, Inc. ("Stemline")
(excluding Japan, China, Taiwan, Korea)

Stemline initiated CBS9106 Phase 1 study in US (solid tumor)
Joint Research (screening) Agreement with Fuji Pharma Valley Project
IDO/TDO Joint Research Agreement with University of Shizuoka

CBP501 Phase 1b study (CBP501 + CDDP + Nivolumub) initiated in US
Joint Research (screening) Agreement with Fujifilm Corporation for the development of immuno-oncology drugs that make use of peptides